Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel polymeric micelle
- Development stage
- Unknown
- Lead developer
- Samyang Biopharmaceuticals
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Intravesical
01
Overview
Nanoxel-M is a polymeric micelle-based nanoformulation of the taxane chemotherapy agent docetaxel, developed by Samyang Biopharmaceuticals (now a division of Samyang Holdings). The formulation utilizes Samyang's proprietary mPEG-PDLLA (methoxy-poly(ethylene glycol)-block-poly(D,L-lactide)) amphiphilic diblock copolymer technology to encapsulate docetaxel into nanoparticles with a mean diameter of 10–50 nm. This delivery system is designed to solubilize docetaxel without the use of polysorbate 80 (Tween 80) or ethanol, which are required for conventional docetaxel formulations (e.g., Taxotere) and are associated with severe hypersensitivity reactions and fluid retention. By eliminating these excipients, Nanoxel-M aims to improve the safety profile and tolerability of docetaxel therapy. The drug received approval in South Korea in 2012 for indications including breast cancer and non-small cell lung cancer. It has also been investigated for intravesical administration in non-muscle invasive bladder cancer (NMIBC) and systemic treatment for head and neck squamous cell carcinoma.
- Brand names
- Nanoxel-MNanoxel
- Other names
- Docetaxel polymeric micelle
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel polymeric micelle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel polymeric micelle.